Home » Newsletters » BioWorld Asia

BioWorld Asia

June 9, 1999

View Archived Issues

SmithKline Passes On Vaccine Being Developed By Amrad

Polymorphism In TNF Promoter Increases Likelihood Of Malaria

Commission Suggests More Controls On Biotech Products

Cerebrus Licenses Alzheimers Drug Thats Reached Phase III

CAT Issues Aptein More Shares

Surveys Show Biotech Out Of Favor With Most Europeans

Relenzas European Approval Helps Renew Interest In Biota

MediGene Validates Target Involved In Heart Failure

TAB Seeks Partner To Move Sepsis Product Into Phase III

Theratechnologies To Create Subsidiary Based On Peptides

LION Adds To Platform, Completes Licensing Deal

Oxford Biomedica Shows Genes Carried to HIV Cells

Shield, Axis Complete Merger, To Focus On In Vitro Products

Pharming Group Prepares To Start Phase III Study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...